AstraZeneca: Imfinzi Granted US Orphan Drug Designation

Date : 07/12/2019 @ 7:46AM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 6803.0  74.0 (1.10%) @ 4:35PM
Astrazeneca share price Chart

AstraZeneca: Imfinzi Granted US Orphan Drug Designation

Astrazeneca (LSE:AZN)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Astrazeneca Charts.
   By Carlo Martuscelli 
 

AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration had awarded its cancer drug Imfinzi orphan drug status as a treatment for small-cell lung cancer.

The designation is given to medicines that aim to treat rare diseases and provides benefits such as market exclusivity and faster regulatory approvals.

Imfinzi is currently approved as a treatment for inoperable stage 3 non-small-cell lung cancer after chemotherapy and radiation therapy.

 

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

 

(END) Dow Jones Newswires

July 12, 2019 02:31 ET (06:31 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20191022 23:50:55